

type of report	Current report
number	57/2012
company	PHARMENA

#### **Conditions and timetable regarding the issue of series C shares with pre-emptive rights**

Pursuant to resolution no. 3 adopted on 21<sup>st</sup> August 2012 during Extraordinary General Meeting of Pharmena S.A. on the Company's share capital increase through issue of series C bearer shares through private placement with pre-emptive rights for hitherto shareholders, the Issuer is carrying out public offering of series C shares with pre-emptive rights.

The goal of the issue of series C shares is to obtain funds for production of tablets for clinical trials (bioavailability testing and phase II), as well as carrying out clinical trials of innovative anti-atherosclerosis medicinal product 1-MNA in the scope of bioavailability.

The issue of series C shares will be carried out through public offering, pursuant to Art. 7 (3.6) with relation to Art. 41 (1.c.2) of act on public offering, conditions governing the introduction of financial instruments to organised trading, and public companies dated 29<sup>th</sup> July 2005 (Dz. U. 2009 no. 185, item 1439, with further amendments).

#### CONDITIONS OF SERIES C SHARES ISSUE:

1. new issue shares (NE) – the issue covers to 781,782 series C ordinary bearer shares,
2. individual pre-emptive rights (JPP) – 6,254,260 individual pre-emptive rights to series C ordinary bearer shares,
3. issue price – 6.50 PLN per one (NE) share,
4. pre-emptive rights ratio – 8 JPP: 1 NE share (eight individual pre-emptive rights entitle to acquire one series C new issue share).

#### TIMETABLE OF SERIES C SHARES ISSUE:

1. 6<sup>th</sup> September 2012 – record day (JPP),
2. from 10<sup>th</sup> to 21<sup>st</sup> September 2012 Warsaw Stock Exchange listing of individual pre-emptive rights (JPP) under the ISIN code: PLPHRMN00029,
3. from 10<sup>th</sup> to 26<sup>th</sup> September 2012 – subscriptions (basic and additional) and payment for series C shares at brokerage houses, which operate the securities accounts in which the pre-emptive rights (JPP) are registered,
4. from 5<sup>th</sup> October 2012 – allocation of shares through realisation of individual pre-emptive rights (JPP).

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

#### **Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wiczorkowska – Vice President of the Board